A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells

Oncogene. 2000 Jan 27;19(4):526-36. doi: 10.1038/sj.onc.1203337.

Abstract

The Raf/MEK/MAP kinase cascade plays a critical role in transducing growth signals from activated cell surface receptors. Using deltaMEK1:ER, a conditionally-active form of MEK1, we demonstrate the ability of this dual specificity protein kinase to abrogate the cytokine-dependency of the human and murine hematopoietic cells lines TF-1, FDC-P1 and FL5.12. Cytokine-independent cells were obtained from TF-1, FDC-P1 and FL5.12 cells at frequencies of 2.5 x 10(-3), 5 x 10(-5) and 10(-7) respectively, indicating that not all cells expressing deltaMEK1:ER were factor-independent. In general, cells that were converted to a cytokine-independent phenotype displayed a higher level of MAP kinase activity in response to deltaMEK1:ER activation than those that remained cytokine-dependent. deltaME-K1:ER-responsive cells could be maintained long-term in the presence of beta-estradiol as well as the estrogen-receptor antagonist 4-Hydroxy-Tamoxifen and the anti-estrogen ICI 164383. Removal of hormone led to the rapid cessation of cell growth in a manner similar to that observed when cytokine is withdrawn from the parental cells. Treatment of deltaMEKI:ER-responsive cells with a specific and selective inhibitor, PD98059, prevented growth in response to beta-estradiol. GM-CSF mRNA transcripts were detected in the MEK1-responsive cells indicating that the activated deltaMEK1:ER may induce a pathway leading to autocrine proliferation. Treatment of MEK1-responsive cells with an anti-GM-CSF antibody, but not a control antibody, suppressed cell growth. The cell lines described here will be useful for elaborating the ability of the MAP kinase pathway to regulate cell proliferation in hematopoietic cells.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Autocrine Communication*
  • Cell Division / drug effects
  • Cell Line
  • Cell Transformation, Neoplastic / genetics*
  • Cytokines / pharmacology
  • Enzyme Activation
  • Enzyme Induction
  • Estradiol / pharmacology
  • Flavonoids / pharmacology
  • Genes, Synthetic
  • Granulocyte-Macrophage Colony-Stimulating Factor / antagonists & inhibitors
  • Granulocyte-Macrophage Colony-Stimulating Factor / immunology
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / enzymology*
  • Hematopoietic Stem Cells / pathology
  • Humans
  • MAP Kinase Kinase 1
  • MAP Kinase Signaling System*
  • Mice
  • Mitogen-Activated Protein Kinase Kinases / biosynthesis
  • Mitogen-Activated Protein Kinase Kinases / genetics
  • Mitogen-Activated Protein Kinase Kinases / physiology*
  • Mutagenesis, Site-Directed
  • Protein Serine-Threonine Kinases / biosynthesis
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / physiology*
  • Receptors, Estrogen / genetics
  • Receptors, Estrogen / metabolism
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / physiology
  • Tamoxifen / analogs & derivatives
  • Tamoxifen / pharmacology
  • Transfection

Substances

  • Antibodies, Monoclonal
  • Cytokines
  • Flavonoids
  • Receptors, Estrogen
  • Recombinant Fusion Proteins
  • Tamoxifen
  • afimoxifene
  • Estradiol
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Protein Serine-Threonine Kinases
  • MAP Kinase Kinase 1
  • MAP2K1 protein, human
  • Map2k1 protein, mouse
  • Mitogen-Activated Protein Kinase Kinases
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one